Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

Author(s):
Boer, S.M. de (0000-0002-8454-1597); Wortman, B.G.; Bosse, T.; Powell, M.E.; Singh, N.; Hollema, H.; Wilson, G.; Chowdhury, M.N.; Mileshkin, L.; Pyman, J.; Katsaros, D.; Carinelli, S.; Fyles, A.; McLachlin, C.M.; Haie-Meder, C.; Duvillard, P.; Nout, R.A.; Verhoeven-Adema, K.W.; Putter, H. (0000-0001-5395-1422); Creutzberg, C.L. (0000-0002-7008-4321); Smit, V.T.H.B.M. (0000-0003-3730-5652); PORTEC Study Grp
Published
2018
Publication type
Article / Letter to editor
endometrial carcinomarandomised trialradiation therapychemotherapypathology reviewhigh risk
Date issued
2018-02-28
Language
English
Is part of
Annals of Oncology (2018), Vol. 29, no. 2, p. 424-430
hdl
1887/75048
doi
10.1093/annonc/mdx753
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834053/pdf/mdx753.pdf